Results of ANDANTE, a randomised clinical study with an anti-IL6 antibody (PF-04236921) in subjects with Crohn's disease who are antitumour necrosis factor inadequate responders
Silvio Danese(IRCCS Ospedale San Raffaele), Stefan Schreiber(Christian-Albrechts-Universität zu Kiel), Séverine Vermeire(KU Leuven), Rupert W. Leong(The University of Sydney), Fabio Cataldi(Pfizer (United States)), Gail M. Comer(Pfizer (United States)), C. Li, Mary K. Maguire(Pfizer (United States)), Gerhard Rogler(University Hospital of Zurich), Peter Hellstern, Gerald Fraser, Pierre Desreumaux(Active Biotech (Sweden)), Ansuman Banerjee, Jean S. Beebe, Anna Kohn, Natalie Rath, Remo Panaccione(University of Calgary)
Unknown
January 1, 2016
Cited by 7
Related Papers
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
|Nature Genetics|2008|2.6k
Genome-wide association study reveals genetic risk underlying Parkinson's disease
|Nature Genetics|2009|2k
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
|The American Journal of Gastroenterology|2015|1.8k
Genome-wide scan reveals association of psoriasis with IL-23 and NF-κB pathways
|Nature Genetics|2009|1.4k